Direct oral anticoagulants
220 results
101 - 200
Antithrombotic agents in primary health care 
Anticoagulation versus placebo for heart failure in sinus rhythm
Resuming oral anticoagulants after a bleed is associated with fewer thrombi and deaths, but more bleeds- Prevention of venous thromboembolism
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- Elevated INR (> 1.5) at admission associated with increased mortality in hospitalized patients who use DOACs
- Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
- ACCP guidelines for antithrombotics in atrial fibrillation
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
- A new bleeding risk score predicts major bleeding better than other scores in elderly patients who take DOACs
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Heart valve operation: patient follow-up and complications
- Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions
- Aspirin no different than rivaroxaban for prevention of VTE after TKA or THA
- Benefits and harms with oral anticoagulation for atrial fibrillation in patients with history of intracranial hemorrhage (COCROACH)
- Anticoagulant therapy in acute (duration less than 48 hours) atrial fibrillation - Image
- Tranexamic acid in people on anticoagulants undergoing minor oral surgery or dental extractions
- Concomitant use of oral anticoagulants and SSRIs associated with increased risk of major bleeding
- Use of antithrombotic medications increases risk of hematuria-related complications
- Deep vein thrombosis
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
- Abelacimab has fewer bleeds than rivaroxaban, but study has several important biases
- Anticoagulant therapy for 6 weeks is noninferior to 3 months for provoked VTE in patients younger than 21 years (Kids-DOTT)
- Nephrotic syndrome
- Vitamin K for improved anticoagulation control in patients receiving warfarin
- Warfarin therapy
- Dabigatran safe and effective for VTE
- Mitral regurgitation
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
- Aortic stenosis
- Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
- Treatment for superficial thrombophlebitis of the leg
- For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Early anticoagulation after ischemic stroke is a safe strategy (ELAN)
- Superficial venous thrombophlebitis
- Antithrombotic treatment after stroke due to intracerebral haemorrhage
- Management of acute atrial fibrillation
- For stable coronary artery disease plus atrial fibrillation, rivaroxaban alone is better than rivaroxaban plus aspirin
- Computerized advice on drug dosage to improve prescribing practice: Cochrane systematic review
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Greater benefit with rivaroxaban than aspirin for extended treatment of VTE
- Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
- Screening for atrial fibrillation in primary care is not effective (VITAL-AF)
- ACC/AHA guidelines for the diagnosis and management of atrial fibrillation
- Electrical cardioversion
- Rivaroxaban is noninferior to warfarin for valvular atrial fibrillation; also associated with fewer strokes
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
- Extended anticoagulation for patients with low-risk pulmonary embolism and cancer has marginal benefit (ON COPE)
- In adults with atrial fibrillation and acute ischemic strokes, early (within 4 days) and delayed (7-10 days) initiation of DOACs have similar outcomes (OPTIMAS)
- Guidelines for the perioperative management of anticoagulants and antiplatelet agents (ACCP)
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Systemic lupus erythematosus (SLE)
- Acute coronary syndrome
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Older patients with atrial fibrillation treated with DOACs have fewer strokes and systemic emboli than those treated with vitamin K antagonists
- Rivaroxaban effective for acute DVT (EINSTEIN)
- Edoxaban noninferior to warfarin for venous thromboembolism anticoagulation
- Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer
- Bleeding risk scores lack accuracy in primary care settings (CACAO)
- ACG guideline on managing acute lower gastrointestinal bleeding
- Transient ischaemic attack (TIA)
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease
- Edoxaban as effective as LMWH for treatment of cancer-associated VTE
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Early DOAC initiation after acute ischemic stroke reduces recurrent strokes without increasing risk of intracranial bleeds (CATALYST)
- Home versus in‐patient treatment for deep vein thrombosis
- Assessment and treatment of a patient with bleeding diathesis
- Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
- Dabigatran cost-effective for AF prophylaxis in some patients, not others
- Extended rivaroxaban prophylaxis following a medical inpatient stay does not provide a net benefit (MARINER)
- Apixaban is noninferior to dalteparin for venous thromboembolism associated with cancer
- Rivaroxaban similar to warfarin for patients with NVAF